Bayer's pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO ...
At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.
Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the ...
A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the ...
Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...
This eBook will go beyond just talking about how to streamline manufacturing but also provide in-depth insights into topics that aren’t always covered to the same degree but are just as important to ...
Being proactive — especially when it comes to testing, process development and preparing for commercialization — can greatly decrease the risk that your CGT will receive a CRL.
2don MSN
Columbus doctors turn to gene therapy for patients in continued fight against sickle cell disease
September is Sickle Cell Awareness Month, and millions of people worldwide are living with the disease. But advances in ...
4don MSN
Preliminary but promising gene therapy shows 75% reduction in Huntington's disease progression
A one-time experimental treatment shows unprecedented success in slowing Huntington's disease, according to UCL researchers.
ProBio recently opened a gene therapy hub in a 128,000-square-foot facility in Mercer County, bringing more than 100 ...
News-Medical.Net on MSN
SynGenSys introduces NK.SET synthetic promoter library to advance natural killer cell therapies
SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma ...
Thanks to in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births. However, this medical advancement created a new challenge: a growing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results